




RealRate

# PHARMACEUTICAL 2022

Traverse Therapeutics Inc  
Rank 331 of 471



The relative strengths and weaknesses of Traverse Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Traverse Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 64% points below the market average of 275%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 582,827              |
| Cost of Goods Sold                          | 6,784                |
| Intangible Assets                           | 148,435              |
| Liabilities, Current                        | 124,088              |
| Liabilities, Non-Current                    | 64,152               |
| Other Assets                                | 34,265               |
| Other Compr. Net Income                     | 340                  |
| Other Expenses                              | 22,669               |
| Other Liabilities                           | 286,281              |
| Other Net Income                            | -17,917              |
| Other Revenues                              | 227,490              |
| Property and Equipment                      | 11,106               |
| Research and Development                    | 210,328              |
| Selling, General and Administrative Expense | 149,883              |

| Output Variable              | Value in<br>1000 USD |
|------------------------------|----------------------|
| Assets                       | 776,633              |
| Liabilities                  | 474,521              |
| Expenses                     | 389,664              |
| Revenues                     | 227,490              |
| Stockholders Equity          | 302,112              |
| Net Income                   | -180,091             |
| Comprehensive Net Income     | -179,921             |
| BaseVar                      | 943,282              |
| ECR before Limited Liability | 77%                  |
| Economic Capital Ratio       | 211%                 |